Nadia Yousaf

4.7k total citations · 1 hit paper
48 papers, 1.2k citations indexed

About

Nadia Yousaf is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Epidemiology. According to data from OpenAlex, Nadia Yousaf has authored 48 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Oncology, 21 papers in Pulmonary and Respiratory Medicine and 6 papers in Epidemiology. Recurrent topics in Nadia Yousaf's work include Cancer Immunotherapy and Biomarkers (15 papers), Lung Cancer Treatments and Mutations (10 papers) and Colorectal Cancer Treatments and Studies (10 papers). Nadia Yousaf is often cited by papers focused on Cancer Immunotherapy and Biomarkers (15 papers), Lung Cancer Treatments and Mutations (10 papers) and Colorectal Cancer Treatments and Studies (10 papers). Nadia Yousaf collaborates with scholars based in United Kingdom, United States and Denmark. Nadia Yousaf's co-authors include James Larkin, Alexander R. Lyon, Javid J. Moslehi, Nicolò Matteo Luca Battisti, Ian Pavord, Surinder S. Birring, Kai K. Lee, Sanjay Popat, Eva Lauridsen and Sérgio Matos and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and The Lancet Oncology.

In The Last Decade

Nadia Yousaf

45 papers receiving 1.2k citations

Hit Papers

Immune checkpoint inhibit... 2018 2026 2020 2023 2018 100 200 300
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Immune checkpoint inhibitors and cardiovascular toxicity
    2018 390 citations Alexander R. Lyon, Nadia Yousaf et al. The Lancet Oncology profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Nadia Yousaf 619 400 229 190 182 48 1.2k
A Catania 232 0.4× 332 0.8× 134 0.6× 67 0.4× 197 1.1× 93 1.5k
Dustin M. Walters 603 1.0× 417 1.0× 187 0.8× 45 0.2× 160 0.9× 44 1.4k
Mehmet Alı Nahıt Şendur 825 1.3× 446 1.1× 94 0.4× 41 0.2× 292 1.6× 183 1.4k
S Caponnetto 485 0.8× 293 0.7× 299 1.3× 69 0.4× 307 1.7× 85 1.2k
Harry Gibbs 386 0.6× 313 0.8× 699 3.1× 48 0.3× 117 0.6× 37 1.2k
Sofia Baka 471 0.8× 640 1.6× 52 0.2× 24 0.1× 222 1.2× 71 1.2k
Mark D. Girgis 856 1.4× 404 1.0× 63 0.3× 31 0.2× 166 0.9× 69 1.6k
Sung‐Hyun Kim 371 0.6× 223 0.6× 73 0.3× 21 0.1× 213 1.2× 105 1.0k
Ιlias Karapantzos 196 0.3× 404 1.0× 46 0.2× 60 0.3× 174 1.0× 51 850
Ching‐Chuan Hsieh 387 0.6× 225 0.6× 28 0.1× 92 0.5× 284 1.6× 58 1.5k

Countries citing papers authored by Nadia Yousaf

Since Specialization
Citations

This map shows the geographic impact of Nadia Yousaf's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nadia Yousaf with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nadia Yousaf more than expected).

Fields of papers citing papers by Nadia Yousaf

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nadia Yousaf. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nadia Yousaf. The network helps show where Nadia Yousaf may publish in the future.

Co-authorship network of co-authors of Nadia Yousaf

This figure shows the co-authorship network connecting the top 25 collaborators of Nadia Yousaf. A scholar is included among the top collaborators of Nadia Yousaf based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nadia Yousaf. Nadia Yousaf is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Rehman, Faisal, Nadia Yousaf, Carol Tan, et al.. (2024). 81 Evaluation of neoadjuvant chemo-immunotherapy for operable non-small cell lung cancer: clinical outcomes and impact on service delivery. Lung Cancer. 190. 107642–107642.
2.
Cui, Wanyuan, Anna Minchom, Jaishree Bhosle, et al.. (2022). Up Front Cell Free DNA Next Generation Sequencing Improves Target Identification in UK First Line Advanced Non-Small Cell Lung Cancer (NSCLC) Patients. SSRN Electronic Journal. 3 indexed citations
3.
Andrés, María Sol, Stuart D. Rosen, John Baksi, et al.. (2022). The spectrum of cardiovascular complications related to immune-checkpoint inhibitor treatment. Cardio-Oncology. 8(1). 21–21. 18 indexed citations
4.
Joshi, Kroopa, Nadia Yousaf, Sanjay Popat, et al.. (2021). Safety monitoring of two and four-weekly adjuvant durvalumab for patients with stage III NSCLC: implications for the COVID-19 pandemic and beyond. Lung Cancer. 156. 147–150. 5 indexed citations
5.
Cui, Wanyuan, Jaishree Bhosle, Anna Minchom, et al.. (2021). 180P Incidence of brain metastases (BM) in newly diagnosed stage IV NSCLC during COVID-19. Journal of Thoracic Oncology. 16(4). S795–S795. 3 indexed citations
6.
Hindocha, Sumeet, Merina Ahmed, Bhupinder Sharma, et al.. (2021). Immune Checkpoint Inhibitor and Radiotherapy-Related Pneumonitis: An Informatics Approach to Determine Real-World Incidence, Severity, Management, and Resource Implications. Frontiers in Medicine. 8. 764563–764563. 5 indexed citations
7.
Cui, Wanyuan, Iris Faull, Rebecca J. Nagy, et al.. (2020). 1352P Circulating tumour (ct) DNA next generation sequencing (NGS) in advanced non-small cell lung cancer (mNSCLC): A UK single institution experience. Annals of Oncology. 31. S867–S867. 1 indexed citations
8.
Spain, Lavinia, Lewis Au, James J. Clark, et al.. (2020). Five-year review of corticosteroid duration and complications in the management of immune checkpoint inhibitor-related diarrhoea and colitis in advanced melanoma. ESMO Open. 5(4). e000585–e000585. 30 indexed citations
9.
Yousaf, Nadia, et al.. (2020). Glucocorticoid use and complications following immune checkpoint inhibitor use in melanoma. Clinical Medicine. 20(2). 163–168. 26 indexed citations
10.
Yousaf, Nadia, et al.. (2019). “Triggers” for early palliative care referral in patients with cancer: a review of urgent unplanned admissions and outcomes. Supportive Care in Cancer. 28(7). 3441–3449. 24 indexed citations
11.
Coleman, Niamh, Andrew Wotherspoon, Nadia Yousaf, & Sanjay Popat. (2019). Transformation to neuroendocrine carcinoma as a resistance mechanism to lorlatinib. Lung Cancer. 134. 117–120. 18 indexed citations
12.
O’Brien, Mary, et al.. (2018). 149P Real-world outcomes with first-line afatinib in EGFR mutant NSCLC adenocarcinoma: A single centre experience exploring effects of dose-reduction. Journal of Thoracic Oncology. 13(4). S89–S90. 3 indexed citations
13.
Lyon, Alexander R., Nadia Yousaf, Nicolò Matteo Luca Battisti, Javid J. Moslehi, & James Larkin. (2018). Immune checkpoint inhibitors and cardiovascular toxicity. The Lancet Oncology. 19(9). e447–e458. 390 indexed citations breakdown →
14.
Spain, Lavinia, Stefan Diem, Komel Khabra, et al.. (2016). Patterns of steroid use in diarrhoea and/or colitis (D/C) from immune checkpoint inhibitors (ICPI). Annals of Oncology. 27. vi374–vi374. 5 indexed citations
15.
Yousaf, Nadia, et al.. (2015). The cost of ipilimumab toxicity. Melanoma Research. 25(3). 259–264. 17 indexed citations
16.
Yousaf, Nadia, et al.. (2012). The long term outcome of patients with unexplained chronic cough. Respiratory Medicine. 107(3). 408–412. 37 indexed citations
17.
Yousaf, Nadia, et al.. (2011). The assessment of quality of life in acute cough with the Leicester Cough Questionnaire (LCQ-acute). PubMed. 7(1). 4–4. 64 indexed citations
18.
Yousaf, Nadia, Surinder S. Birring, & Ian Pavord. (2009). THE LONG-TERM OUTCOME OF PATIENTS WITH UNEXPLAINED CHRONIC COUGH. Thorax. 64. 1 indexed citations
19.
Yousaf, Nadia, Sérgio Matos, Surinder S. Birring, & Ian Pavord. (2009). FACTORS AFFECTING COUGH FREQUENCY IN A MIXED POPULATION. Thorax. 64. 3 indexed citations
20.
Yousaf, Nadia, et al.. (2008). NORMAL RANGE FOR 24-HOUR COUGH FREQUENCY. Thorax. 63. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by A Catania Breakdown of academic impact, for papers by Dustin M. Walters Breakdown of academic impact, for papers by Mehmet Alı Nahıt Şendur Breakdown of academic impact, for papers by S Caponnetto Breakdown of academic impact, for papers by Harry Gibbs Breakdown of academic impact, for papers by Sofia Baka Breakdown of academic impact, for papers by Mark D. Girgis Breakdown of academic impact, for papers by Sung‐Hyun Kim Breakdown of academic impact, for papers by Ιlias Karapantzos Breakdown of academic impact, for papers by Ching‐Chuan Hsieh
Rankless by CCL
2026